Stock Market Today – S&P 500 (SPX), Nasdaq (COMP), Dow (DJIA) Jump as Oil Craters and Wall Street Holds Its Breath for Nvidia

Three straight sessions of losses. Treasury yields at levels nobody had penciled in for 2026. An oil price embedded with a war premium that had been suffocating equity multiples for weeks. Wednesday morning changed the tone — not because any of those structural problems got solved, but because one thing moved in the right direction, and that was enough.

Three tankers transited the Strait of Hormuz overnight. Two Chinese, one South Korean. That was the headline. Brent crude futures sold off 4% to $106.87. WTI collapsed 4.3% to $99.70 — back below $100 for the first time since the Iran escalation premium started building in. And from that single data point, the entire session re-priced. When the biggest source of inflationary pressure in the market takes a 4% haircut in a single morning, everything connected to rate sensitivity starts to look cheap again. That's the mechanism. That's why you saw the S&P 500 (SPX) up 52.20 points, or +0.71%, to 7,405.81. That's why the Nasdaq Composite (COMP) added 272.46 points, or +1.05%, to 26,143.17. The Dow Jones Industrial Average (DJIA) climbed 318.57 points, or +0.65%, to 49,682.45. And the Russell 2000 (RUT) — the one that actually tells you whether this is real or a megacap squeeze — gained 50.71 points, or +1.85%, to 2,797.79. The small-cap index outperforming by 80 basis points over the large-cap benchmark is not a narrow AI headline trade. That is broad, domestic, rate-sensitive risk appetite coming back to life.

The Treasury Market Finally Stopped Bleeding — But Don't Call It a Recovery

The bond market had been in open revolt for days heading into Wednesday. The 30-year U.S. Treasury yield briefly touched 5.197% on Tuesday — its highest print since July 2007, almost 19 full years. Think about that for a second. The 10-year hit 4.687% intraday, the highest since January 2025. Strategists at HSBC had already labeled the complex officially in a "danger zone." BMO Capital Markets strategist Ian Lyngen was out with commentary warning that further yield moves would start feeding back into equities in a way that couldn't be contained. That's the scenario nobody wanted — a reflexive loop where bond selloffs compress equity multiples, which then weaken consumer balance sheets, which then weakens growth expectations, which then pushes more people into bonds as defensive positioning.

Wednesday interrupted that loop. The 10-year pulled back 6 basis points to 4.607%. The 30-year eased more than 1 basis point off 5.174%. These are not big numbers in bond terms, but the direction shift mattered enormously for positioning. Duration-sensitive growth stocks had been bleeding for three sessions. A single day of yield relief gave that trade room to breathe.

The context underneath all of this is the Federal Reserve. Kevin Warsh — Trump's nominee who replaced Jerome Powell as chair — is operating in a situation that looks increasingly like 2022's stagflation rerun: inflation reigniting, oil embedding a war premium, and a labor market that hasn't cracked. Market participants are now pricing in a 58% probability of a rate hike by December, up from 40% just days prior, based on CME FedWatch data. The current fed funds rate sits at 3.50%–3.75%, and a hike would be the first since 2023's tightening campaign concluded. The April FOMC minutes were due at 2 p.m. ET Wednesday, and the market was watching for exactly how divided the committee is — sources described the April decision to hold as carrying the most dissenting votes in over three decades. That's not a unified Fed. That's a committee arguing about which direction to move while the data keeps coming in hot.

The U.S. dollar index (DXY) edged 0.2% lower to 99.17 — a muted move that reflected the complexity of the macro setup, where lower oil is dollar-negative through the petrodollar flow channel, but inflation fears and potential rate hikes are dollar-positive. Gold futures settled at $4,525 an ounce, up 0.3%, with spot touching $4,537.90 during the session. The VIX fell 1.60% to 17.77. That's not a fearless market — the high teens on the VIX is not complacency. It's a market that has dialed back short-term panic while keeping medium-term hedges on. Bitcoin (BTC-USD) traded at $77,287.78, up $843.19, or +1.10%, moving in rough alignment with risk sentiment.

Arm Holdings (NASDAQ:ARM) Detonates Higher — +14.93% to $256.46 on an Earnings Beat That Rewrote the Risk-Reward

If you were watching one stock define the session's character in the first two hours, it was Arm Holdings (NASDAQ:ARM). The stock gained $33.31, or +14.93%, to $256.46 on volume of 10.418 million shares — running 26% above its three-month average of 8.26 million. At a $272.9 billion market cap, ARM has now appreciated over 71% over 52 weeks and entered Wednesday already above its prior range high of $239.50. Wednesday's close at $256.46 is uncharted territory for this stock. The move was driven by a quarterly earnings print that surpassed even optimistic sell-side estimates, with licensing revenue and royalty income both surprising to the upside. The thesis here doesn't require nuance: every Nvidia GPU, every custom AI accelerator, every cloud chip that hyperscalers are designing in-house — a substantial portion of it runs on an Arm architecture. Royalty income scales as that installed base multiplies. Management's tone on demand visibility came across as more confident than the setup implied, which is what caused the short covering that accelerated the morning move.

The complication is real and worth watching. The FTC has opened a probe into Arm's licensing practices, specifically looking at whether the company's architectural dominance is being leveraged in ways that approach anticompetitive behavior. ARM also announced an ESOP expansion that raised dilution questions. The stock looked at both of those headlines and kept ripping. That tells you everything about positioning going in: too many people were underweight, too many had hedged on the regulatory overhang, and the earnings print forced them to cover. Smart money had been noted as waiting for a specific level to add — the stock ran through whatever that level was before noon.

Nvidia (NASDAQ:NVDA) +1.84% Into the Most Important Earnings Report of the Quarter

Everything in this session happened in the shadow of Nvidia (NASDAQ:NVDA). Every position in semiconductors, every allocation to AI infrastructure, every hedge against the AI capex narrative — all of it was waiting for the number after the bell. Shares were up 1.84% on the day heading into the release. The company entered Wednesday's session with a $5.34 trillion market cap, the largest publicly traded company in the world by a significant margin. Goldman Sachs chief U.S. equity strategist Ben Snider quantified the weight of this name precisely: Nvidia has contributed approximately 20% of the S&P 500's total return in 2026 and nearly the same share of the broad index's earnings growth. When a single company represents one-fifth of index returns, every quarterly report becomes a macro event. Every fund manager on the planet had to have a view on what NVDA said after the close — not just for its own P&L impact but for what it said about the durability of AI infrastructure spending heading into the second half of the year. Shares are up roughly 18% year-to-date through Tuesday's close, outperforming both the S&P 500 and the Magnificent Seven peer group.

The semiconductor complex broadly priced in an NVDA beat ahead of the print. Intel (NASDAQ:INTC) jumped 5.80%, staging a genuine recovery from weeks of underperformance tied to manufacturing execution concerns and competitive pressure. Micron Technology (NASDAQ:MU) gained more than 3%. Qualcomm (NASDAQ:QCOM) was also up more than 3%. SanDisk (NASDAQ:SNDK) added 1.40%. Marvell Technology (NASDAQ:MRVL) surged more than 5%. The iShares Semiconductor ETF (SOXX) gained more than 2% — the first real bounce after a significant pullback from the complex's earlier highs. Analog Devices (NASDAQ:ADI) was an outlier on the downside, declining about 1.5% despite reporting better-than-expected fiscal Q2 adjusted EPS of $3.09 versus the $2.88 consensus and topping revenue estimates as well. The market shrugged at the beat and sold it anyway — a sign that in this macro environment, good numbers aren't always enough when the multiple is questioned.

Astera Labs (NASDAQ:ALAB) +11.87%, Super Micro (NASDAQ:SMCI) +8.19% — The AI Infrastructure Stack Gets Priced for a Clean NVDA Print

Astera Labs (NASDAQ:ALAB) gained $29.00, or +11.87%, to $273.26 on volume of 4.207 million shares. Its three-month average is 5.307 million, meaning this move came on lighter-than-average volume — which is actually constructive. It means it wasn't frantic retail chasing; it was positioning ahead of a catalyst. ALAB builds the connectivity chips and platform solutions that bind together GPU clusters, CPUs, and memory in AI accelerator racks. It's a direct derivative of the AI build-out, a pure-play infrastructure beneficiary that moves with NVDA sentiment. The stock is up 165.01% over 52 weeks, closing Wednesday above its prior 52-week high of $262.90. That's a breakout in an environment where most breakouts have been faded.

Super Micro Computer (NASDAQ:SMCI) gained $2.50, or +8.19%, to $33.06 on 14.635 million shares — below its three-month average of 37.814 million. SMCI has had a complicated year. It's still down 26.63% over the past 52 weeks despite Wednesday's move, having carved a base near $19.48. The narrative remains intact: it's the fastest-growing AI server integrator in the market, sitting at the intersection of every hyperscaler capex decision. Dell Technologies (NYSE:DELL) and Hewlett Packard Enterprise (NYSE:HPE) both participated — DELL up 3.33%, HPE up 2.61% — which confirms this wasn't an SMCI-specific squeeze. The entire server and storage AI infrastructure stack was being accumulated ahead of the NVDA print.

Navitas Semiconductor (NASDAQ:NVTS) added $1.62, or +8.36%, to $21.06. Volume of 10.899 million against a 28.886 million average. The stock has run 917.28% over 52 weeks — not a typo. Lattice Semiconductor (NASDAQ:LSCC) was up $9.46, or +7.61%, to $133.70 — a $18.318 billion market cap name trading at 851x trailing earnings with a 166.95% 52-week gain that can only be justified if you believe the FPGA-based AI-at-the-edge positioning compounds for years from here. The market is making exactly that bet.

Immunovant (NASDAQ:IMVT) Goes Nuclear — +30.41% to $34.28 on Clinical Data That Made the Earnings Miss Completely Irrelevant

The percentage winner of the session — and it wasn't close — was Immunovant (NASDAQ:IMVT). The stock added $7.99, or +30.41%, to $34.28 on volume of 10.174 million shares against a three-month average of 1.395 million. That's more than seven times normal volume. The catalyst was clinical trial data on the company's FcRn inhibitor program, which showed efficacy results compelling enough that the market didn't care about the earnings miss. The quarterly numbers were below estimates — revenue, EPS, the works — but nobody was trading on that. The clinical read validated the therapeutic mechanism in a way that changes the probability distribution on the drug program, and that's worth far more than a quarterly P&L.

IMVT carries a $7.008 billion market cap and has been up 82.44% over 52 weeks. Its 52-week range was $13.79–$30.16 heading into Wednesday. Today's close at $34.28 is a clean, decisive breakout above the prior high. This is what happens when biotech data surprises — the stock doesn't drift higher, it gaps and continues. The question from here is whether the institutional accumulation behind the seven-times-average volume represents real conviction or event-driven positioning that gets reduced over the following sessions.

Roivant Sciences (NASDAQ:ROIV) gained $3.77, or +13.35%, to $31.98 on 6.573 million shares. The Q4 earnings call was the driver, with the $23.021 billion market cap company up 158.57% over 52 weeks. Roivant's business model — spinning out individual drug programs into focused subsidiaries, then capturing royalty streams and equity appreciation — is one of the more intellectually defensible structures in biotech, and the market is rewarding it as several portfolio companies hit late-stage milestones. ImmunityBio (NASDAQ:IBRX) added $0.63, or +8.12%, to $8.39 after the FDA accepted the company's sBLA filing for expanded use of its bladder cancer therapy. An FDA acceptance is not an approval, but it is a concrete regulatory milestone that removes one layer of uncertainty. Erasca (NASDAQ:ERAS) gained 9.84% to $11.34. Summit Therapeutics (NASDAQ:SMMT) added 8.55% to $17.20. Guardant Health (NASDAQ:GH) closed up $9.71, or +9.89%, to $107.90 on a major clinical win in liquid biopsy-based cancer detection. Volume of 813,765 was well below its 1.972 million average — conviction buying, not retail momentum. At a $14.308 billion market cap and up 164.73% over 52 weeks, GH is a name that has been repricing over months as its platform accumulates real-world clinical validation.

Target (NYSE:TGT) Beats the Number and Gets Punished Anyway — Then TJX (NYSE:TJX) Shows You Exactly Why

Target (NYSE:TGT) reported Q1 earnings of $1.71 per share on $25.44 billion in revenue. Consensus was $1.46 EPS and $24.64 billion revenue. Both lines beaten, full-year net sales growth guide lifted to 4% from the prior 2%. Clean beat-and-raise on paper. The stock fell 5.10% to $120.75 by late morning. That reaction needs an explanation, and the explanation is: the market doesn't trust the guide. WTI was at $99.70 after the session's oil slide — still elevated historically. The Iran war has embedded a persistent gasoline cost that is compressing Target's core consumer faster than the topline suggests, and the street read the 4% growth forecast as a number being made before the demand data from June gets counted. When guidance comes with question marks about macro durability, a beat at the current quarter's price is not enough to hold the stock at these levels.

TJX Companies (NYSE:TJX) had the opposite day. The off-price retailer reported $1.19 EPS on $14.32 billion revenue against consensus of $1.02 EPS and $14.02 billion — a $0.17 per share beat on the bottom line, which is substantial. Shares jumped more than 5.5%. The contrast between TJX and TGT in the same session is a clean expression of where consumer spending is rotating in this environment. When gas prices are elevated and real wages are being eaten by goods inflation, trade-down is not a theoretical risk — it's a proven behavioral shift. Loop Capital analyst Anthony Chukumba published analysis Wednesday tracking the correlation between quarterly average gasoline prices and comparable store sales growth across retailers. The finding was direct: Five Below (NASDAQ:FIVE) and discount optical retailer National Vision show the strongest positive correlations with gas prices. Off-price and deep discount are the structures built for exactly this environment. On the other side, Ollie's Bargain Outlet and Grocery Outlet's sales growth showed the strongest negative correlations — which is counterintuitive until you understand that those formats traffic in a customer who was already economically stressed and doesn't have discretionary compression to absorb.

Lowe's (NYSE:LOW) beat estimates — $3.03 adjusted EPS on $23.08 billion revenue against $2.97 and $22.97 billion consensus — and reaffirmed full-year guidance. Shares fell more than 2% before partially recovering to close around $217.46. The reaffirmation without a raise is what disappointed. With the 10-year Treasury above 4.60%, mortgage rates remain suppressed enough on affordability that housing transaction volume isn't recovering. No housing transactions means no move-in renovation spending, which is Lowe's core demand driver. Beating a quarter while the structural demand headwind remains unchanged isn't enough to move a stock higher.

CAVA Group (NYSE:CAVA) was one of the cleanest earners of the session. The Mediterranean fast-casual chain beat both lines — $0.20 EPS versus $0.18 expected, $438 million revenue versus $411 million — and lifted full-year adjusted EBITDA guidance to $181–$191 million from the prior $176–$184 million range. Shares gained 6.68% to $83.34. Toll Brothers (NYSE:TOL) added 2% in after-hours trading after reporting fiscal Q2 EPS of $2.72 on $2.51 billion revenue, both above consensus of $2.57 and $2.42 billion respectively. Red Robin Gourmet Burgers (NASDAQ:RRGB) surged 14% in extended hours after posting adjusted EPS of $0.13 against a breakeven expectation, with $378.3 million revenue beating the $362.1 million estimate. VF Corp. (NYSE:VFC) rose roughly 4% in premarket after reporting fiscal Q4 revenue of $2.17 billion — up 1% year-over-year, above the $2.12 billion estimate. The North Face revenue grew 12%, Timberland 8%. Vans slipped 1% but showed a return to growth in Americas direct-to-consumer for the first time in over four years. CEO Bracken Darrell's line that VFC had "returned to a full year of growth for the first time in three years" is the kind of sentence that makes institutional portfolio managers reconsider an underweight.

Energy Splits in Half — Crude Names Leak, Clean Energy and Nuclear Ignite

The energy sector was net negative on the session as WTI's slide below $100 punished upstream names broadly. But the internals were a bifurcation that tells a longer story about where capital is rotating. Traditional oil and gas underperformed. Clean energy and nuclear did the opposite.

T1 Energy (NASDAQ:TE) surged 27.03% to $8.74 on 40.668 million shares — more than double its 18.042 million three-month average. It's now up 574.51% over 52 weeks. Talen Energy (NASDAQ:TLN) added $27.97, or +8.89%, to $342.54. Bloom Energy (NYSE:BE) gained $22.39, or +8.57%, to $283.73 — a name up 1,335.15% over 52 weeks, a number that would be unbelievable if it weren't sitting right there in the data. The power thesis around AI data center energy demand is what drives that number. Every new GPU cluster requires a power infrastructure commitment, and Bloom's solid oxide fuel cell technology positions it as a distributed generation solution for facilities that can't wait years for grid capacity. Oklo (NYSE:OKLO) added $4.78, or +8.56%, to $60.67 on 4.707 million shares. ReNew Energy Global (NASDAQ:RNW) gained 8.22% to $5.79. Enphase Energy (NASDAQ:ENPH) added $4.20, or +8.98%, to $50.96 after Goldman Sachs raised its price target to $57 — Goldman seeing residential solar as a re-emerging trade after months of rate-driven margin compression.